Chugai Pharmaceutical Co., Ltd. (CHGCY)

Chugai Pharmaceutical Co. Income Statement

Financials in millions JPY. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	1,036,075	1,111,367	1,259,946	999,759	786,946	686,184
Revenue Growth (YoY)	-14.49%	-11.79%	26.02%	27.04%	14.68%	18.35%
Cost of Revenue	334,928	418,358	476,251	338,147	273,465	266,071
Gross Profit	701,147	693,009	783,695	661,612	513,481	420,113
Selling, General & Admin	107,546	112,580	100,760	102,416	94,401	101,574
Research & Development	173,268	164,764	149,626	137,299	117,850	107,942
Other Operating Expenses	-1,306	0	-2,134	-2,540	-1,504	-3,124
Operating Expenses	265,960	277,344	250,386	239,715	212,251	209,516
Operating Income	435,189	415,665	533,309	421,897	301,230	210,597
Interest Income	4,971	1,482	182	166	121	109
Interest Expense	27	27	61	48	62	125
Other Expense / Income	-3,916	-26,701	2,264	2,630	3,101	2,688
Pretax Income	444,048	443,821	531,166	419,385	298,188	207,893
Income Tax	117,676	118,349	156,737	116,390	83,455	50,333
Net Income	326,373	325,472	374,429	302,995	214,733	157,560
Net Income Growth	3.23%	-13.08%	23.58%	41.10%	36.29%	70.36%
Shares Outstanding (Basic)	1,645	1,645	1,645	1,644	1,643	1,642
Shares Outstanding (Diluted)	1,646	1,645	1,645	1,645	1,645	1,645
Shares Change	0.01%	0.01%	0.01%	0.01%	0.03%	-50.00%
EPS (Basic)	198.37	197.83	227.64	184.29	130.66	95.95
EPS (Diluted)	198.34	197.80	227.57	184.17	130.53	95.81
EPS Growth	32.63%	-13.08%	23.57%	41.09%	36.24%	240.72%
Free Cash Flow	324,698	337,068	172,873	206,760	143,624	145,464
Free Cash Flow Per Share	197.31	204.84	105.07	125.67	87.31	88.45
Gross Margin	67.67%	62.36%	62.20%	66.18%	65.25%	61.22%
Operating Margin	42.00%	37.40%	42.33%	42.20%	38.28%	30.69%
Profit Margin	31.50%	29.29%	29.72%	30.31%	27.29%	22.96%
Free Cash Flow Margin	31.34%	30.33%	13.72%	20.68%	18.25%	21.20%
Effective Tax Rate	26.50%	26.67%	29.51%	27.75%	27.99%	24.21%
EBITDA	439,372	447,405	531,227	419,433	298,250	208,018
EBITDA Margin	42.41%	40.26%	42.16%	41.95%	37.90%	30.32%
Depreciation & Amortization	2,700	31,740	31,434	30,868	30,476	26,401
EBIT	436,672	415,665	499,793	388,565	267,774	181,617
EBIT Margin	42.15%	37.40%	39.67%	38.87%	34.03%	26.47%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.